Collegium Pharmaceutical’s (COLL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in a research note issued to investors on Wednesday. They currently have a $21.00 price target on the specialty pharmaceutical company’s stock.

COLL has been the topic of several other reports. Piper Jaffray Companies reiterated a buy rating and set a $14.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. BidaskClub downgraded Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Friday, August 4th. Zacks Investment Research upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Monday, August 14th. Jefferies Group LLC reiterated a buy rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, Needham & Company LLC reiterated a buy rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $20.00.

Collegium Pharmaceutical (NASDAQ COLL) traded up $1.38 during midday trading on Wednesday, reaching $14.09. The company had a trading volume of 2,270,100 shares, compared to its average volume of 701,444. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $18.02.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. Collegium Pharmaceutical’s quarterly revenue was up 2814.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.13) earnings per share. equities analysts anticipate that Collegium Pharmaceutical will post -2.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/collegium-pharmaceuticals-coll-buy-rating-reaffirmed-at-hc-wainwright/1768044.html.

Several institutional investors have recently made changes to their positions in COLL. Morgan Stanley lifted its position in shares of Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after acquiring an additional 772,464 shares in the last quarter. Sectoral Asset Management Inc lifted its position in shares of Collegium Pharmaceutical by 41.4% in the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock valued at $22,627,000 after acquiring an additional 529,503 shares in the last quarter. Citadel Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 773.8% in the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after acquiring an additional 481,771 shares in the last quarter. Macquarie Group Ltd. lifted its position in shares of Collegium Pharmaceutical by 37.1% in the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock valued at $13,995,000 after acquiring an additional 302,892 shares in the last quarter. Finally, Prudential Financial Inc. lifted its position in shares of Collegium Pharmaceutical by 62.8% in the third quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock valued at $5,843,000 after acquiring an additional 214,860 shares in the last quarter. Institutional investors and hedge funds own 83.25% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Red Sox Want Sluggers, Giancarlo Stanton May Become Available


Leave a Reply

 
© 2006-2017 BBNS.